Citations (144)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L. Harwood, Marta Compte, Rocío Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belén Blanco, Simon Lykkemark, Ángel Ramírez-Fernández, Mariola Ferreras-Gutiérrez, Carmen Domínguez-Alonso, Laura Díez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J. Blanco, Cruz Santos, José L. Rodríguez-Peralto, Laura Sanz & Luis Álvarez-Vallina. (2023) A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response. OncoImmunology 12:1.
Read now
Read now
Viktor A. Urban, Alexander I. Davidovskii & Valery G. Veresov. (2023) Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions. Journal of Biomolecular Structure and Dynamics 41:11, pages 5345-5361.
Read now
Read now
Hulin Jin, Vittorio D'Urso, Berend Neuteboom, Sean D. McKenna, Rene Schweickhardt, Alec W. Gross, Yves Fomekong Nanfack, Andrea Paoletti, Carina Carter, Lars Toleikis, Markus Fluck, Juergen Scheuenpflug & Ti Cai. (2021) Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. OncoImmunology 10:1.
Read now
Read now
Panagiota Economopoulou, Ioannis Kotsantis & Aristotelis Bamias. (2020) A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma. Expert Opinion on Drug Safety 19:8, pages 955-960.
Read now
Read now
Anna Manzo, Guido Carillio, Agnese Montanino, Vincenzo Sforza, Giuliano Palumbo, Giovanna Esposito, Raffaele Costanzo, Claudia Sandomenico, Carmine La Manna, Nicola Martucci, Antonello La Rocca, Giuseppe De Luca, Maria Carmela Piccirillo, Rossella De Cecio, Gerardo Botti, Giuseppe Totaro, Paolo Muto, Carmine Picone, Nicola Normanno & Alessandro Morabito. (2020) The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. Expert Opinion on Drug Safety 19:7, pages 775-783.
Read now
Read now
Sumin Son, Jinho Park, Hyodeok Seo, Hyun Tae Lee, Yong-Seok Heo & Hak-Sung Kim. (2020) A small-sized protein binder specific for human PD-1 effectively suppresses the tumour growth in tumour mouse model. Journal of Drug Targeting 28:4, pages 419-427.
Read now
Read now
Sangeetha M. Reddy, Emma Carroll & Rita Nanda. (2020) Atezolizumab for the treatment of breast cancer. Expert Review of Anticancer Therapy 20:3, pages 151-158.
Read now
Read now
Danilo Rocco, Umberto Malapelle, Marzia Del Re, Luigi Della Gravara, Francesco Pepe, Romano Danesi, Giancarlo Troncone & Cesare Gridelli. (2020) Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Drug Metabolism & Toxicology 16:2, pages 87-96.
Read now
Read now
Yan Wang, Donghui Pan, Chenrong Huang, Bingliang Chen, Mingzhu Li, Shuaixiang Zhou, Lizhen Wang, Min Wu, Xinyu Wang, Yicong Bian, Junjie Yan, Junjian Liu, Min Yang & Liyan Miao. (2020) Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody. mAbs 12:1.
Read now
Read now
Yan Tie, Hui Yang, Rui Zhao, Heng Zheng, Daoke Yang, Jingyi Zhao & Ming Liu. (2019) Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis. Drug Design, Development and Therapy 13, pages 523-538.
Read now
Read now
Anne-Sophie Heimes & Marcus Schmidt. (2019) Atezolizumab for the treatment of triple-negative breast cancer. Expert Opinion on Investigational Drugs 28:1, pages 1-5.
Read now
Read now
M. Xipell, I. Victoria, V. Hoffmann, J. Villarreal, A. García-Herrera, O. Reig, L. Rodas, M. Blasco, E. Poch, B. Mellado & L. F. Quintana. (2018) Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. OncoImmunology 7:7.
Read now
Read now
Gonzalo Tapia Rico & Timothy J. Price. (2018) Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. Expert Opinion on Biological Therapy 18:4, pages 449-457.
Read now
Read now
Neil J. Shah, William J. Kelly, Stephen V. Liu, Karin Choquette & Alexander Spira. (2018) Product review on the Anti-PD-L1 antibody atezolizumab. Human Vaccines & Immunotherapeutics 14:2, pages 269-276.
Read now
Read now
Ahmet Murat Aydin, Solomon L Woldu, Ryan C Hutchinson, Martin Boegemann, Aditya Bagrodia, Yair Lotan, Vitaly Margulis & Laura-Maria Krabbe. (2017) Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy 10, pages 1487-1502.
Read now
Read now
Nagashree Seetharamu, Isabel R Preeshagul & Kevin M Sullivan. (2017) New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab. Lung Cancer: Targets and Therapy 8, pages 67-78.
Read now
Read now
Fernando C. Santini & Charles M. Rudin. (2017) Atezolizumab for the treatment of non-small cell lung cancer. Expert Review of Clinical Pharmacology 10:9, pages 935-945.
Read now
Read now
Johan Vansteenkiste, Els Wauters, Keunchil Park, Achim Rittmeyer, Alan Sandler & Alexander Spira. (2017) Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opinion on Biological Therapy 17:6, pages 781-789.
Read now
Read now
Gerhard Hamilton & Barbara Rath. (2017) Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opinion on Biological Therapy 17:4, pages 515-523.
Read now
Read now
Rutveej Patel, Megan Bock, Charles F. Polotti & Sammy Elsamra. (2017) Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 225-232.
Read now
Read now
Articles from other publishers (124)
Fabrice Yves Ndjana lessomo, Oscar Onayi Mandizadza, Chishimba Mukuka & Zhi-Quan Wang. (2023) A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. European Journal of Medical Research 28:1.
Crossref
Crossref
Mark J. Ratain & Garth W. Strohbehn. (2023) Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?. European Journal of Cancer 194, pages 113349.
Crossref
Crossref
Sophie Marolleau, Alice Mogenet, Clara Boeri, Mourad Hamimed, Joseph Ciccolini & Laurent Greillier. (2023) Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients. CPT: Pharmacometrics & Systems Pharmacology 12:11, pages 1795-1803.
Crossref
Crossref
David Hodson, Hitesh Mistry, Sofia Guzzetti, Michael Davies, Anna Staniszewska, Paul Farrington, Elaine Cadogan, James Yates, Leon Aarons & Kayode Ogungbenro. (2023)
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the
DNA
damage response pathway
. CPT: Pharmacometrics & Systems Pharmacology 12:11, pages 1640-1652.
Crossref
Crossref
Siyan Xu, Na Zhang, Mikael L. Rinne, Haiying Sun & Andrew M. Stein. (2023)
Sabatolimab (
MBG453
) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors
. CPT: Pharmacometrics & Systems Pharmacology 12:11, pages 1653-1665.
Crossref
Crossref
Silvia Godínez-Palma, Edith González-González, Frida Ramírez-Villedas, Circe Garzón-Guzmán, Luis Vallejo-Castillo, Gregorio Carballo-Uicab, Gabriel Marcelín-Jiménez, Dany Batista, Sonia M. Pérez-Tapia & Juan C. Almagro. (2023) Efficacy, Pharmacokinetics, and Toxicity Profiles of a Broad Anti-SARS-CoV-2 Neutralizing Antibody. Viruses 15:8, pages 1733.
Crossref
Crossref
Qi Zhang, Jian Zhang, Haijun Zhong, Ying Yuan, Lei Yang, Qingyuan Zhang, Dongmei Ji, Jifang Gong, Jing Li, Zhenling Yao, Chuan Qi, Jianming Wang, Lingmin Lu, Michael Shi, Xueming Qian, Lin Shen, Jian Li & Xichun Hu. (2023) Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma. Cancer Immunology, Immunotherapy 72:8, pages 2729-2739.
Crossref
Crossref
Ji Won Han & Jeong Won Jang. (2023) Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences 24:14, pages 11799.
Crossref
Crossref
Aditi Mulgaonkar, Durga Udayakumar, Yaxing Yang, Shelby Harris, Orhan K. Öz, Praveen Ramakrishnan Geethakumari & Xiankai Sun. (2023) Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy. Frontiers in Medicine 10.
Crossref
Crossref
Cody J. Peer, Keith T. Schmidt, Oluwatobi Arisa, William J. Richardson, Koosha Paydary, Daniel A. Goldstein, James L. Gulley, William D. Figg & Mark J. Ratain. (2023) In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation. The Journal of Clinical Pharmacology 63:6, pages 672-680.
Crossref
Crossref
Chan Kim, Hannah Yang & Hong Jae Chon. (2023) High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply. JAMA Oncology 9:5, pages 725.
Crossref
Crossref
Guang-Long Ma & Wei-Feng Lin. (2023) Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy. Military Medical Research 10:1.
Crossref
Crossref
Yi Sun, Or-yam Revach, Seth Anderson, Emily A. Kessler, Clara H. Wolfe, Anne Jenney, Caitlin E. Mills, Emily J. Robitschek, Thomas G. R. Davis, Sarah Kim, Amina Fu, Xiang Ma, Jia Gwee, Payal Tiwari, Peter P. Du, Princy Sindurakar, Jun Tian, Arnav Mehta, Alexis M. Schneider, Keren Yizhak, Moshe Sade-Feldman, Thomas LaSalle, Tatyana Sharova, Hongyan Xie, Shuming Liu, William A. Michaud, Rodrigo Saad-Beretta, Kathleen B. Yates, Arvin Iracheta-Vellve, Johan K. E. Spetz, Xingping Qin, Kristopher A. Sarosiek, Gao Zhang, Jong Wook Kim, Mack Y. Su, Angelina M. Cicerchia, Martin Q. Rasmussen, Samuel J. Klempner, Dejan Juric, Sara I. Pai, David M. Miller, Anita Giobbie-Hurder, Jonathan H. Chen, Karin Pelka, Dennie T. Frederick, Susanna Stinson, Elena Ivanova, Amir R. Aref, Cloud P. Paweletz, David A. Barbie, Debattama R. Sen, David E. Fisher, Ryan B. Corcoran, Nir Hacohen, Peter K. Sorger, Keith T. Flaherty, Genevieve M. Boland, Robert T. Manguso & Russell W. Jenkins. (2023) Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature 615:7950, pages 158-167.
Crossref
Crossref
Isabel González-Crespo, Antonio Gómez-Caamaño, Óscar López Pouso, John D. FenwickJuan Pardo-Montero. (2023) A Biomathematical Model of Tumor Response to Radioimmunotherapy With αPDL1 and αCTLA4. IEEE/ACM Transactions on Computational Biology and Bioinformatics 20:2, pages 808-821.
Crossref
Crossref
Akhilesh Mishra, Dhiraj Kumar, Kuldeep Gupta, Gabriela Lofland, Ajay Kumar Sharma, Dhanush S. Banka, Robert F. Hobbs, Robert F. Dannals, Steven P. Rowe, Edward Gabrielson & Sridhar Nimmagadda. (2023) Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics. Clinical Cancer Research 29:3, pages 581-591.
Crossref
Crossref
Petros Nikolopoulos, George Liapis, Panagiotis Giannakopoulos, Ioannis Kotsantis, Konstantinos Drouzas & Sophia Lionaki. (2023) Rapidly Progressive Pauci-Immune Glomerulonephritis with Aberrant Fibrinoid Necrosis Associated with Atezolizumab, an Immune Check Point Inhibitor: A Case Report and Review of Literature. Antibodies 12:1, pages 10.
Crossref
Crossref
Yanqing Li, Ziyu Luo, Xinxing Wang, Songtao Zhang, Hu Hei & Jianwu Qin. (2022) Design of new drugs for medullary thyroid carcinoma. Frontiers in Oncology 12.
Crossref
Crossref
Christophe Maritaz, Sophie Broutin, Nathalie Chaput, Aurélien Marabelle & Angelo Paci. (2022) Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
AYESHA SOHAIL, ROBIA ARIF, QURAT UL AIN AZIM, ALESSANDRO NUTINI & KHALED A. GEPREEL. (2022) PIECEWISE FRACTIONAL-ORDER MODELING OF THE BREAST CANCER EPIDEMIOLOGY AFTER THE ATEZOLIZUMAB TREATMENT. Fractals 30:08.
Crossref
Crossref
Mayu Yamamoto, Taiki Kurino, Reiko Matsuda, Haleigh Sakura Jones, Yoshito Nakamura, Taisei Kanamori, Atushi B. Tsuji, Aya Sugyo, Ryota Tsuda, Yui Matsumoto, Yu Sakurai, Hiroyuki Suzuki, Makoto Sano, Kensuke Osada, Tomoya Uehara, Yukimoto Ishii, Hidetaka Akita, Yasushi Arano, Akihiro Hisaka & Hiroto Hatakeyama. (2022) Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect. Journal of Controlled Release 352, pages 328-337.
Crossref
Crossref
Thareeya Phetphoung, Ashwini Malla, Kaewta Rattanapisit, Nuttapat Pisuttinusart, Naruechai Damrongyot, Keerati Joyjamras, Pithi Chanvorachote, Tanapati Phakham, Tossapon Wongtangprasert, Richard Strasser, Chatchai Chaotham & Waranyoo Phoolcharoen. (2022) Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition. PLOS ONE 17:11, pages e0274737.
Crossref
Crossref
Dan Li, Feng Wang, Jinquan Jiang, Xingguo Hou, Jin Ding, Zilei Wang, Yan Chen, Teli Liu, Zhi Yang & Hua Zhu. (2022) Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging. Molecular Pharmaceutics 19:11, pages 4382-4389.
Crossref
Crossref
Qing Wu, Wei Qian, Xiaoli Sun & Shaojie Jiang. (2022) Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Huan-Ling Guo, Xiao-Yan Xie & Ming Xu. (2022) Application of nanomaterials in combined thermal ablation and immunotherapy for liver tumors. World Chinese Journal of Digestology 30:19, pages 829-837.
Crossref
Crossref
Lei Zhou, Haifeng Liang, Yuxiang Ge, Wang Ding, Qing Chen, Taiwei Zhang, Lan Xiao, Yulin Li, Jian Dong, Xiaowen He, Fengfeng Xue & Libo Jiang. (2022) Precisely Targeted Nano‐Controller of PD‐L1 Level for Non‐Small Cell Lung Cancer Spinal Metastasis Immunotherapy. Advanced Healthcare Materials 11:20.
Crossref
Crossref
Weize Huang, Felix Stader, Phyllis Chan, Colby S. Shemesh, Yuan Chen, Katherine L. Gill, Hannah M. Jones, Linzhong Li, Gianluca Rossato, Benjamin Wu, Jin Y. Jin & Pascal Chanu. (2022) Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. Frontiers in Pharmacology 13.
Crossref
Crossref
Yun Jung Choi, Jun Young Park, Ye Lim Cho, Ju Ri Chae, Hojin Cho & Won Jun Kang. (2022) In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer. Biochemical and Biophysical Research Communications 620, pages 105-112.
Crossref
Crossref
Xinying Guo & Xinyi Sheng. (2022) Drug discovery of PD-L1 inhibitor Atezolizumab. Highlights in Science, Engineering and Technology 8, pages 660-667.
Crossref
Crossref
Andrea Zanello, Massimo Bortolotti, Stefania Maiello, Andrea Bolognesi & Letizia Polito. (2022) Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?. Frontiers in Pharmacology 13.
Crossref
Crossref
Sreeneeranj Kasichayanula, Sandhya Mandlekar, Vittal Shivva, Maulik Patel & Sandhya Girish. (2022) Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy. Clinical and Translational Science 15:8, pages 1818-1837.
Crossref
Crossref
Maria Lia Palomba, Guillaume Cartron, Leslie Popplewell, Vincent Ribrag, Jason Westin, Ling-Yuh Huw, Shefali Agarwal, Mahesh Shivhare, Wan-Jen Hong, Aparna Raval, Alice C. Chang, Elicia Penuel & Franck Morschhauser. (2022) Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. Clinical Lymphoma Myeloma and Leukemia 22:7, pages 504-512.
Crossref
Crossref
Yulia Vugmeyster, Ana-Marija Grisic, Brigitte Brockhaus, Peter Rueckert, Mary Ruisi, Haiqing Dai & Akash Khandelwal. (2022) Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors. Clinical Pharmacokinetics 61:7, pages 985-995.
Crossref
Crossref
Mengjie Jiang, Yujie Hu, Gang Lin & Chao Chen. (2022) Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. Frontiers in Oncology 12.
Crossref
Crossref
Pierre-Florent Petit, Raphaële Bombart, Pierre-Hubert Desimpel, Stefan Naulaerts, Laurie Thouvenel, Jean-François Collet, Benoit J. Van den Eynde & Jingjing Zhu. (2022) T Cell–Mediated Targeted Delivery of Anti–PD-L1 Nanobody Overcomes Poor Antibody Penetration and Improves PD-L1 Blocking at the Tumor Site. Cancer Immunology Research 10:6, pages 713-727.
Crossref
Crossref
Juncheng Zou, Cong Li, Xinyue Zhang, Tao Huang, Nurmuhammat Kehriman, Wen Kuang, Xin Hu, Youqi Yan & Xiaomei Ling. (2022) Novel electrochemical biosensors for investigating the interactions between atezolizumab and PD-1/PD-L1 and screening their small-molecular inhibitors. Biosensors and Bioelectronics: X 10, pages 100146.
Crossref
Crossref
Huanling Guo, Jinsheng Huang, Yang Tan, Wenxin Wu, Tongyi Huang, Nan Zhang, Shuling Chen, Chunyang Zhang, Xiaoyan Xie, Xintao Shuai & Ming Xu. (2022) Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. Nano Today 43, pages 101425.
Crossref
Crossref
Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg & Mark J. Ratain. (2022) Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. The Journal of Clinical Pharmacology 62:4, pages 532-540.
Crossref
Crossref
Naoki Shijubou, Takeyuki Sawai, Taku Hatakeyama, Satoru Munakata & Masami Yamazoe. (2022) Alveolar Hemorrhage Caused by the Combination of Immune Checkpoint Inhibitors (ICIs) and Angiogenesis Inhibitors: The Underlying Long-Term Vascular Endothelial Growth Factor (VEGF) Inhibition. Cureus.
Crossref
Crossref
Pratibha Pandey, Fahad Khan, Huda A. Qari, Tarun Kumar Upadhyay, Abdulhameed F. Alkhateeb & Mohammad Oves. (2022) Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals 15:3, pages 335.
Crossref
Crossref
Shujun Dong, Ian Nessler, Anna Kopp, Baron Rubahamya & Greg M. Thurber. (2022) Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics. Frontiers in Pharmacology 13.
Crossref
Crossref
Aaron T. Gerds, Bart L. Scott, Peter GreenbergTara L. LinDaniel A. Pollyea, Amit Verma, Monique Dail, Yuning FengCherie Green, Connie MaBruno C. Medeiros, Mark Yan, Kasra Yousefi & William Donnellan. (2022) Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances 6:4, pages 1152-1161.
Crossref
Crossref
Patrick Schöffski, Daniel S W Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Niladri Roy Chowdhury, Catherine A Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak & David S Hong. (2022) Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer 10:2, pages e003776.
Crossref
Crossref
Min Kwan Kwon, Junhwan Kim, Jonghwa Ahn, Chang-Yun Woo, Hyeonjeong Kim, Hye-Seon Oh, Mingee Lee, Seungha Hwang, Keun Hoi Park, Young Hak Lee, Jakyung Yu, Sujeung Kang & Hyo-Ju Son. (2022) Clinical Features and Risk Factors of Adrenal Insufficiency in Patients With Cancer Admitted to the Hospitalist-Managed Medical Unit. Journal of Korean Medical Science 37:28.
Crossref
Crossref
Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung-Bae Kim, Ava Kwong, Guenther G. Steger, Esther Zamora Adelantado, Francois P. Duhoux, Richard Greil, Irene Kuter, Yen-Shen Lu, Ariadna Tibau, Mustafa Özgüroğlu, Christian W. Scholz, Christian F. Singer, Estela Vega, Pauline Wimberger, Claudio Zamagni, Xuan-Mai Couillebault, Liqiong Fan, Nelson Guerreiro, Jennifer Mataraza, Janna Sand-Dejmek & Arlene Chan. (2022) A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clinical Cancer Research 28:1, pages 106-115.
Crossref
Crossref
Benjamin Wu, Nitzan Sternheim, Priya Agarwal, Julia Suchomel, Shweta Vadhavkar, Rene Bruno, Marcus Ballinger, Coen A. Bernaards, Phyllis Chan, Jane Ruppel, Jin Jin, Sandhya Girish, Amita Joshi & Valerie Quarmby. (2021) Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Clinical and Translational Science 15:1, pages 130-140.
Crossref
Crossref
Ligong Lu, Meixiao Zhan, Xian-Yang Li, Hui Zhang, Danielle J. Dauphars, Jun Jiang, Hua Yin, Shi-You Li, Sheng Luo, Yong Li & You-Wen He. (2022) Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology 3, pages 118-127.
Crossref
Crossref
René J. Boosman, Jacobus A. Burgers, Egbert F. Smit, Neeltje Steeghs, Anthonie J. van der Wekken, Jos H. Beijnen, Alwin D. R. Huitema & Rob ter Heine. (2021) Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. Drugs 82:1, pages 15-32.
Crossref
Crossref
Cody J. Peer, Sara M. Zimmerman, William D. Figg, Daniel A. Goldstein & Mark J. Ratain. (2021) Subcutaneous Atezolizumab: A Jab Without a Benefit. Clinical Pharmacology in Drug Development 11:1, pages 134-135.
Crossref
Crossref
Lei He, Liangliang Wang, Zhisong Wang, Tiantian Li, Hui Chen, Yaning Zhang, Zeping Hu, Dimiter S. Dimitrov, Juanjuan Du & Xuebin Liao. (2021) Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry 64:21, pages 15716-15726.
Crossref
Crossref
Yusheng WangKun ShangNinggang ZhangJian ZhaoBangwei Cao. (2021) Tumor-Associated Macrophage-Derived Exosomes Promote the Progression of Gastric Cancer by Regulating the P38MAPK Signaling Pathway and the Immune Checkpoint PD-L1. Cancer Biotherapy and Radiopharmaceuticals.
Crossref
Crossref
Enriqueta Felip, Mauricio Burotto, Zanete Zvirbule, Luis A. Herraez‐Baranda, Pascal Chanu, Smita Kshirsagar, Vidya Maiya, Phyllis Chan, Emanuela Pozzi, Mathilde Marchand, Marion Monchalin, Kunihiko Tanaka, Nadia Tosti, Bei Wang & Eleonora Restuccia. (2021) Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer. Clinical Pharmacology in Drug Development 10:10, pages 1142-1155.
Crossref
Crossref
Ingrid Julienne Georgette Burvenich, Yit Wooi Goh, Nancy Guo, Hui Kong Gan, Angela Rigopoulos, Diana Cao, Zhanqi Liu, Uwe Ackermann, Christian Werner Wichmann, Alexander Franklin McDonald, Nhi Huynh, Graeme Joseph O’Keefe, Sylvia Jie Gong, Fiona Elizabeth Scott, Linghui Li, Wanping Geng, Anup Zutshi, Yan Lan & Andrew Mark Scott. (2021) Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa. European Journal of Nuclear Medicine and Molecular Imaging 48:10, pages 3075-3088.
Crossref
Crossref
Yu Rebecca Miao, Kaushik N. Thakkar, Jin Qian, Mihalis S. Kariolis, Wei Huang, Saravanan Nandagopal, Teddy Tat Chi Yang, Anh N. Diep, Gerald Maxwell Cherf, Yu Xu, Eui Jung Moon, Yiren Xiao, Haizea Alemany, Tiane Li, Wenhua Yu, Bo Wei, Erinn B. Rankin & Amato J. Giaccia. (2021) Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. Clinical Cancer Research 27:15, pages 4435-4448.
Crossref
Crossref
Yawei Liu, Robert Bockermann, Mahdieh Hadi, Iman Safari, Belinda Carrion, Marie Kveiborg & Shohreh Issazadeh-Navikas. (2020) ADAM12 is a costimulatory molecule that determines Th1 cell fate and mediates tissue inflammation. Cellular & Molecular Immunology 18:8, pages 1904-1919.
Crossref
Crossref
Begum Alaybeyoglu, Ho Wa Cheng, Kshama A. Doshi, Vishruti Makani & Andrew M. Stein. (2021) Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included.. Journal of Pharmacokinetics and Pharmacodynamics 48:4, pages 447-464.
Crossref
Crossref
Chen-Hsi Chou & Li-Feng Hsu. (2020) Authors’ reply to letters to the editor “model-based simulation to support the extended dosing regimens of atezolizumab”. European Journal of Clinical Pharmacology 77:7, pages 1067-1068.
Crossref
Crossref
Benjamin Wu, Stephanie N. Liu, Marcus Ballinger, Nitzan Sternheim, Hina Patel, Julien Mazieres & Rene Bruno. (2021) Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab. European Journal of Clinical Pharmacology 77:7, pages 1065-1066.
Crossref
Crossref
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 13:8, pages 637-644.
Crossref
Crossref
Xiufeng Liu, Yi Lu & Shukui Qin. (2021) Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncology 17:17, pages 2243-2256.
Crossref
Crossref
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran & Hussein A. Tawbi. (2021) Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery 11:6, pages 1368-1397.
Crossref
Crossref
Jinyoung Park, Yoon-Seo Jang, Jeong-Hae Choi, Miheon Ryu, Gyoo-Cheon Kim, June-Ho Byun, Dae-Seok Hwang & Uk-Kyu Kim. (2021) Anticancer Efficacy of Nonthermal Plasma Therapy Combined with PD-L1 Antibody Conjugated Gold Nanoparticles on Oral Squamous Cell Carcinoma. Applied Sciences 11:10, pages 4559.
Crossref
Crossref
Reza Beheshti Zavareh, Stephan H. Spangenberg, Ashley Woods, Francisco Martínez-Peña & Luke L. Lairson. (2021) HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. Cell Chemical Biology 28:2, pages 158-168.e5.
Crossref
Crossref
Jinsheng Huang, Zecong Xiao, Yongcheng An, Shisong Han, Wei Wu, Yong Wang, Yu Guo & Xintao Shuai. (2021) Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy. Biomaterials 269, pages 120636.
Crossref
Crossref
Mark Stroh, Michelle Green, Bjorn L. Millard, Joshua F. Apgar, John M. Burke, Will Garner, Hong Lu, Susan K. Lyman, Luc R. Desnoyers, Jennifer Richardson, Alison Hannah & W. Michael Kavanaugh. (2020) Model‐Informed Drug Development of the Masked Anti‑PD‑L1 Antibody CX‐072. Clinical Pharmacology & Therapeutics 109:2, pages 383-393.
Crossref
Crossref
Colby S. Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs, Shweta Vadhavkar, René Bruno & Benjamin Wu. (2021) Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. Liver Cancer 10:5, pages 485-499.
Crossref
Crossref
Hsuan-Ping Chang, Se Jin Kim & Dhaval K. Shah. (2021) Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations. Journal of Pharmaceutical Sciences 110:1, pages 446-457.
Crossref
Crossref
Sudha Warrier, Manasi Patil, Sanyukta Bhansali, Lavanya Varier & Gautam Sethi. (2021) Designing precision medicine panels for drug refractory cancers targeting cancer stemness traits. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875:1, pages 188475.
Crossref
Crossref
Chen-Hsi Chou & Li-Feng Hsu. (2020) Model-based simulation to support the extended dosing regimens of atezolizumab. European Journal of Clinical Pharmacology 77:1, pages 87-93.
Crossref
Crossref
K. V. Ulyanova, A. A. Kazarov, M. S. Pantyushenko, A. A. Olenev, I. V. Lyagoskin & V. M. Simonov. (2020) Development and Validation of a Biolayer Interferometry Method for Determination of Human Anti-PD-1 Monoclonal Antibody Concentration in Cynomolgus Serum. BIOpreparations. Prevention, Diagnosis, Treatment 20:4, pages 257-267.
Crossref
Crossref
Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, David S. Shames, Meghna Das Thakur, Jane Shi, Lorna Bailey, Shweta Vadhavkar, Xian He, Wei Zhang & René Bruno. (2020) Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden. Pharmacology Research & Perspectives 8:6.
Crossref
Crossref
Hao Cai, Victor Yip, M. Violet Lee, Sylvia Wong, Ola Saad, Shuguang Ma, Nina Ljumanovic, S. Cyrus Khojasteh, Amrita V. Kamath & Ben-Quan Shen. (2020)
Characterization of Tissue Distribution, Catabolism, and Elimination of an Anti–
Staphylococcus aureus
THIOMAB Antibody-Antibiotic Conjugate in Rats
. Drug Metabolism and Disposition 48:11, pages 1161-1168.
Crossref
Crossref
Sridhar Nimmagadda. (2020) Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers 12:11, pages 3173.
Crossref
Crossref
Eleonora Rofi, Marzia Del Re, Elena Arrigoni, Mimma Rizzo, Lorenzo Fontanelli, Stefania Crucitta, Giulia Gianfilippo, Giuliana Restante, Stefano Fogli, Camillo Porta, Romano Danesi & Manuela Schmidinger. (2020) Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology 154, pages 102891.
Crossref
Crossref
Sameer Ahamd Guru, Mamta P. Sumi, Rashid Mir, Ajaz Ahmad Waza, Musadiq Ahmad Bhat, Mariyam Zuberi, Promod Lali & Alpana Saxena. (2020) Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Human Cell 33:4, pages 1099-1111.
Crossref
Crossref
Corrine Ying Xuan Chua, Jeremy Ho, Antonia Susnjar, Graziano Lolli, Nicola Di Trani, Federica Pesaresi, Mengying Zhang, Elizabeth Nance & Alessandro Grattoni. (2020) Intratumoral Nanofluidic System for Enhancing Tumor Biodistribution of Agonist CD40 Antibody. Advanced Therapeutics 3:10.
Crossref
Crossref
Wu-Yi Xiao, Yi Wang, Hong-Wei An, Dayong Hou, Muhetaerjiang Mamuti, Man-Di Wang, Jie Wang, Wanhai Xu, Liming Hu & Hao Wang. (2020) Click Reaction-Assisted Peptide Immune Checkpoint Blockade for Solid Tumor Treatment. ACS Applied Materials & Interfaces 12:36, pages 40042-40051.
Crossref
Crossref
Cody J. Peer, Daniel A. Goldstein, Jennifer C. Goodell, Ryan Nguyen, William D. Figg & Mark J. Ratain. (2020) Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. British Journal of Clinical Pharmacology 86:9, pages 1769-1777.
Crossref
Crossref
Yulia Vugmeyster, Justin Wilkins, Andre Koenig, Samer El Bawab, Isabelle Dussault, Laureen S. Ojalvo, Samrita De Banerjee, Lena Klopp‐Schulze & Akash Khandelwal. (2020) Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1. Clinical Pharmacology & Therapeutics 108:3, pages 566-574.
Crossref
Crossref
Corrine Ying Xuan Chua, Jeremy Ho, Sandra Demaria, Mauro Ferrari & Alessandro Grattoni. (2020) Emerging Technologies for Local Cancer Treatment. Advanced Therapeutics 3:9.
Crossref
Crossref
Klaus Eyer, Carlos Castrillon, Guilhem Chenon, Jérôme Bibette, Pierre Bruhns, Andrew D. Griffiths & Jean Baudry. (2020) The Quantitative Assessment of the Secreted IgG Repertoire after Recall to Evaluate the Quality of Immunizations. The Journal of Immunology 205:4, pages 1176-1184.
Crossref
Crossref
Daniel A. Goldstein, Garth W. Strohbehn, Anthony V. Serritella, David A. Hyman, Allen S. Lichter & Mark J. Ratain. (2020) Interventional Pharmacoeconomics. The Cancer Journal 26:4, pages 330-334.
Crossref
Crossref
Yoko Tsukita, Eisaku Miyauchi, Masahide Fukudo, Takaaki Sasaki & Masakazu Ichinose. (2020) Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab. European Journal of Cancer 133, pages 22-24.
Crossref
Crossref
Sara Zalba, Ana M. Contreras-Sandoval, Eva Martisova, Reno Debets, Christian Smerdou & María Jesús Garrido. (2020) Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs. Pharmaceutics 12:6, pages 595.
Crossref
Crossref
Kartik Sehgal, Daniel B. Costa & Deepa Rangachari. (2020) Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. Frontiers in Oncology 10.
Crossref
Crossref
Omid Hamid, Rene Bruno, Marcella Fasso, Carol O'Hear & Benjamin Wu. (2020) Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab—Response. Clinical Cancer Research 26:10, pages 2436-2436.
Crossref
Crossref
Daniel A. Goldstein & Mark J. Ratain. (2020) Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab—Letter. Clinical Cancer Research 26:10, pages 2435-2435.
Crossref
Crossref
Robert Kernstock, Gizette Sperinde, Deborah Finco, Roslyn Davis & Diana Montgomery. (2020) Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody. The AAPS Journal 22:3.
Crossref
Crossref
Aude Desnoyer, Sophie Broutin, Julia Delahousse, Christophe Maritaz, Louis Blondel, Olivier Mir, Nathalie Chaput & Angelo Paci. (2020) Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. European Journal of Cancer 128, pages 119-128.
Crossref
Crossref
Etienne Chatelut, Félicien Le Louedec & Gérard Milano. (2019) Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology. Clinical Pharmacokinetics 59:3, pages 287-296.
Crossref
Crossref
Taiki Kurino, Reiko Matsuda, Ayu Terui, Hiroyuki Suzuki, Tomomi Kokubo, Tomoya Uehara, Yasushi Arano, Akihiro Hisaka & Hiroto Hatakeyama. (2020) Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. Journal for ImmunoTherapy of Cancer 8:1, pages e000400.
Crossref
Crossref
R. Jiao, K.J.H. Allen, M.E. Malo, D. Rickles & E. Dadachova. (2020) Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model. International Journal of Molecular Sciences 21:3, pages 773.
Crossref
Crossref
Athanasios Mavratzas, Julia Seitz, Katharina Smetanay, Andreas Schneeweiss, Dirk Jäger & Carlo Fremd. (2020) Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncology 16:3, pages 4439-4453.
Crossref
Crossref
Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin & Sandhya Girish. (2019) Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Akintunde Akinleye & Zoaib Rasool. (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Eleonora Rofi, Marzia Del Re, Elena Arrigoni, Mimma Rizzo, Lorenzo Fontanelli, Stefania Crucitta, Giulia Gianfilippo, Giuliana Restante, Stefano Fogli, Camillo Porta, Romano Danesi & Manuela Schmidinger. (2019) Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology 144, pages 102812.
Crossref
Crossref
Daniel A. Goldstein & Mark J. Ratain. (2019) Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemotherapy and Pharmacology 84:6, pages 1153-1155.
Crossref
Crossref
Kari M. Morrissey, Mathilde Marchand, Hina Patel, Rong Zhang, Benjamin Wu, H. Phyllis Chan, Almut Mecke, Sandhya Girish, Jin Y. Jin, Helen R. Winter & René Bruno. (2019) Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemotherapy and Pharmacology 84:6, pages 1257-1267.
Crossref
Crossref
Kerry A. Whalen, Brian H. White, James M. Quinn, Kristina Kriksciukaite, Rossitza Alargova, Tsun P. Au Yeung, Patrick Bazinet, Adam Brockman, Michelle M. DuPont, Haley Oller, James Gifford, Charles-Andre Lemelin, Patrick Lim Soo, Samantha Perino, Benoît Moreau, Gitanjali Sharma, Rajesh Shinde, Beata Sweryda-Krawiec, Mark T. Bilodeau & Richard Wooster. (2019) Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. Molecular Cancer Therapeutics 18:11, pages 1926-1936.
Crossref
Crossref
Amal Kamal Abdel-Aziz, Mona Kamal Saadeldin, Paolo D'Amico, Stefania Orecchioni, Francesco Bertolini, Giuseppe Curigliano & Saverio Minucci. (2019) Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. European Journal of Cancer 122, pages 22-41.
Crossref
Crossref
Tomasz Grabowski, Joannes A. A. Reijers, Artur Burmańczuk & Anna Chełmońska-Soyta. (2019) Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies. European Journal of Drug Metabolism and Pharmacokinetics 44:5, pages 585-589.
Crossref
Crossref
Mark Stroh, Jason Sagert, John M. Burke, Joshua F. Apgar, Lin Lin, Bjorn L. Millard & W. Michael Kavanaugh. (2019) Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated Antibody. CPT: Pharmacometrics & Systems Pharmacology 8:9, pages 676-684.
Crossref
Crossref
Yuhan ZhangChangming FangRongsheng E. WangYing WangHui GuoChao GuoLijun Zhao, Shuhong Li, Xia LiPeter G. SchultzYu J. Cao & Feng Wang. (2019) A tumor-targeted immune checkpoint blocker. Proceedings of the National Academy of Sciences 116:32, pages 15889-15894.
Crossref
Crossref
Sameed Ahmed, Miandra Ellis, Hongshan Li, Luca Pallucchini & Andrew M. Stein. (2019) Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems. Journal of Pharmacokinetics and Pharmacodynamics 46:3, pages 287-304.
Crossref
Crossref
Leah A. Mitchell, Kader Yagiz, Andrew Hofacre, Sophie Viaud, Anthony W. Munday, Fernando Lopez Espinoza, Daniel Mendoza, Maria E. Rodriguez-Aguirre, Simon Bergqvist, Ali Haghighi, Marin V. Miner, William P. Accomando, Cynthia Burrascano, Dawn Gammon, Harry E. Gruber, Douglas J. Jolly & Amy H. Lin. (2019) PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget 10:23, pages 2252-2269.
Crossref
Crossref
Dhiraj Kumar, Ala Lisok, Elyes Dahmane, Matthew McCoy, Sagar Shelake, Samit Chatterjee, Viola Allaj, Polina Sysa-Shah, Bryan Wharram, Wojciech G. Lesniak, Ellen Tully, Edward Gabrielson, Elizabeth M. Jaffee, John T. Poirier, Charles M. Rudin, Jogarao V.S. Gobburu, Martin G. Pomper & Sridhar Nimmagadda. (2019) Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation 129:2, pages 616-630.
Crossref
Crossref
Michael R. Harrison, Megan A. McNamara, Tian Zhang & Brant A. Inman. 2019. Immune Checkpoint Inhibitors in Cancer. Immune Checkpoint Inhibitors in Cancer
115
133
.
Sridhar Nimmagadda, Sagar Shelake & Martin G. Pomper. 2019. Radiopharmaceutical Chemistry. Radiopharmaceutical Chemistry
569
582
.
Danielle Mandikian, Isabel Figueroa, Amy Oldendorp, Hanine Rafidi, Sheila Ulufatu, Michelle G. Schweiger, Jessica A. Couch, Noel Dybdal, Sean B. Joseph, Saileta Prabhu, Gregory Z. Ferl & C. Andrew Boswell. (2018) Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology. The AAPS Journal 20:6.
Crossref
Crossref
Meric Ovacik & Kedan Lin. (2018) Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clinical and Translational Science 11:6, pages 540-552.
Crossref
Crossref
Rachel Ryu & Kristina E. Ward. (2018) Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects. Frontiers in Oncology 8.
Crossref
Crossref
Zineb Hamilou, Pernelle Lavaud & Yohann Loriot. (2018) Atezolizumab in urothelial bladder carcinoma. Future Oncology 14:4, pages 331-341.
Crossref
Crossref
Russell W. Jenkins, Amir R. Aref, Patrick H. Lizotte, Elena Ivanova, Susanna Stinson, Chensheng W. Zhou, Michaela Bowden, Jiehui Deng, Hongye Liu, Diana Miao, Meng Xiao He, William Walker, Gao Zhang, Tian Tian, Chaoran Cheng, Zhi Wei, Sangeetha Palakurthi, Mark Bittinger, Hans Vitzthum, Jong Wook Kim, Ashley Merlino, Max Quinn, Chandrasekar Venkataramani, Joshua A. Kaplan, Andrew Portell, Prafulla C. Gokhale, Bart Phillips, Alicia Smart, Asaf Rotem, Robert E. Jones, Lauren Keogh, Maria Anguiano, Lance Stapleton, Zhiheng Jia, Michal Barzily-Rokni, Israel Cañadas, Tran C. Thai, Marc R. Hammond, Raven Vlahos, Eric S. Wang, Hua Zhang, Shuai Li, Glenn J. Hanna, Wei Huang, Mai P. Hoang, Adriano Piris, Jean-Pierre Eliane, Anat O. Stemmer-Rachamimov, Lisa Cameron, Mei-Ju Su, Parin Shah, Benjamin Izar, Manisha Thakuria, Nicole R. LeBoeuf, Guilherme Rabinowits, Viswanath Gunda, Sareh Parangi, James M. Cleary, Brian C. Miller, Shunsuke Kitajima, Rohit Thummalapalli, Benchun Miao, Thanh U. Barbie, Vivek Sivathanu, Joshua Wong, William G. Richards, Raphael Bueno, Charles H. Yoon, Juan Miret, Meenhard Herlyn, Levi A. Garraway, Eliezer M. Van Allen, Gordon J. Freeman, Paul T. Kirschmeier, Jochen H. Lorch, Patrick A. Ott, F. Stephen Hodi, Keith T. Flaherty, Roger D. Kamm, Genevieve M. Boland, Kwok-Kin Wong, David Dornan, Cloud Peter Paweletz & David A. Barbie. (2018)
Ex Vivo
Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
. Cancer Discovery 8:2, pages 196-215.
Crossref
Crossref
Alice Bernard-Tessier, Clément Bonnet, Pernelle Lavaud, Marco Gizzi, Yohann Loriot & Christophe Massard. (2018) Atézolizumab (Tecentriq ® ) : activité, indication et modalités d’utilisation dans les carcinomes urothéliaux localement avancés ou métastatiques. Bulletin du Cancer 105:2, pages 140-145.
Crossref
Crossref
Adrienne E. Borrie & Saman Maleki Vareki. 2018. Biology of T Cells - Part A. Biology of T Cells - Part A
201
276
.
Andrea Cignarella & Chiara Bolego. 2018. Immunopharmacology and Inflammation. Immunopharmacology and Inflammation
179
190
.
Kenta Haraya, Tatsuhiko Tachibana & Junichi Nezu. (2017) Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metabolism and Pharmacokinetics 32:4, pages 208-217.
Crossref
Crossref
M Stroh, H Winter, M Marchand, L Claret, S Eppler, J Ruppel, O Abidoye, SL Teng, WT Lin, S Dayog, R Bruno, J Jin & S Girish. (2017) Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. Clinical Pharmacology & Therapeutics 102:2, pages 305-312.
Crossref
Crossref
Mauro Cataldi, Chiara Vigliotti, Teresa Mosca, MariaRosaria Cammarota & Domenico Capone. (2017) Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes. International Journal of Molecular Sciences 18:6, pages 1249.
Crossref
Crossref
David M. Francis & Susan N. Thomas. (2017) Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Advanced Drug Delivery Reviews 114, pages 33-42.
Crossref
Crossref
Brant A. Inman, Thomas A. Longo, Sundhar Ramalingam & Michael R. Harrison. (2017) Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer. Clinical Cancer Research 23:8, pages 1886-1890.
Crossref
Crossref
Samit Chatterjee, Wojciech G. Lesniak, Michelle S. Miller, Ala Lisok, Emilia Sikorska, Bryan Wharram, Dhiraj Kumar, Matthew Gabrielson, Martin G. Pomper, Sandra B. Gabelli & Sridhar Nimmagadda. (2017) Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochemical and Biophysical Research Communications 483:1, pages 258-263.
Crossref
Crossref
Matthew A. GreenJ. Aubrey Waddell & Dominic A. SolimandoJrJr. (2016) Drug Monographs: Atezolizumab and Everolimus. Hospital Pharmacy 51:10, pages 810-814.
Crossref
Crossref
Wojciech G. Lesniak, Samit Chatterjee, Matthew Gabrielson, Ala Lisok, Bryan Wharram, Martin G. Pomper & Sridhar Nimmagadda. (2016)
PD-L1 Detection in Tumors Using [
64
Cu]Atezolizumab with PET
. Bioconjugate Chemistry 27:9, pages 2103-2110.
Crossref
Crossref
Yongshu Li, Fangfei Li, Feng Jiang, Xiaoqing Lv, Rongjiang Zhang, Aiping Lu & Ge Zhang. (2016) A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences 17:7, pages 1151.
Crossref
Crossref